ICP-105

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameICP-105
Drug Alias NameICP-105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsSolid tumoursLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Innocare Pharma Tech Co LtdBeijing Tiancheng Pharmaceutical Technology Co LtdNanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnoCare Pharma LtdBeijing Tiancheng Pharmaceutical Technology Co LtdNanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd
Inactive CompaniesBeijing Innocare Pharma Tech Co Ltd
Active IndicationsLiver Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A